Equillium, Inc. develops novel therapeutics for severe autoimmune and inflammatory disorders. News about EQ centers on EQ504, the company’s investigational aryl hydrocarbon receptor, or AhR, modulator, including preclinical data, clinical-development planning, and disease-area positioning in ulcerative colitis, other gastrointestinal diseases, and inflammatory lung diseases.
Company updates also cover financing activity, operating results, corporate presentations, and equity-award disclosures under Nasdaq inducement-grant rules. These items reflect Equillium’s focus on immunobiology, immunomodulatory assets, capital resources for research and development, and public-company compensation and governance practices.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology firm, announced that CEO Bruce Steel and CMO Krishna Polu will present at the Jefferies Virtual Healthcare Conference on June 2, 2020, at 1:30 PM ET. This presentation will focus on Equillium's innovative efforts in treating severe autoimmune and inflammatory disorders, particularly through its product candidate itolizumab (EQ001). The live webcast can be accessed on the company’s website and will be available for replay for 30 days.
Equillium, Inc. (Nasdaq: EQ) reported its first quarter 2020 financial results, revealing a net loss of $7.8 million, equating to $(0.45) per share, which is an increase compared to a $6.0 million loss or $(0.34) per share in Q1 2019. R&D expenses rose to $4.7 million, driven by clinical trial activities, while G&A expenses slightly increased to $2.7 million. Equillium's cash and equivalents amounted to $47.7 million, down from $53.1 million at the end of 2019. The company paused some clinical trials due to the COVID-19 pandemic but expects initial data from the EQUATE trial in the second half of 2020.
Equillium (Nasdaq: EQ), a biotechnology firm, will participate in the 2020 RBC Capital Markets Virtual Global Healthcare Conference on May 20, 2020. The discussion will include CEO Bruce Steel and CMO Krishna Polu, starting at 3:05 PM ET. The event will be broadcast live, and replays will be available for 30 days. Equillium is focused on developing itolizumab, a first-in-class monoclonal antibody targeting the CD6-ALCAM pathway, aimed at treating severe autoimmune and inflammatory disorders.